MaaT Pharma Launches European Clinical Trial in Severe Acute Graft-versus-Host Disease for patients receiving allogeneic Hematopoietic Stem Cell Transplantation
8 March 2018

MaaT Pharma Launches European Clinical Trial in Severe Acute Graft-versus-Host Disease for patients receiving allogeneic Hematopoietic Stem Cell Transplantation

MaaT Pharma, a clinical-stage biopharmaceutical company, received authorization from competent authorities to launch its phase II prospective multicenter clinical trial in...

Read the press release

By continuing your browsing on this site, you accept the use of cookies to carry out statistics of anonymous visits. Read more

Authorize Refuse